AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath
10'000 Hours Investment Overview When I last covered AstraZeneca (NASDAQ:AZN), the Anglo / Swedish Pharmaceuticals giant for Seeking Alpha, it was to advise readers that "It's OK To Buy Dip On Q4 Bottom-Line Miss". Analysts were …